SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Don Dunlap who wrote (3984)12/21/1997 3:44:00 PM
From: MisterED  Read Replies (1) of 23519
 
The unfair part of the Barron's article is that they try to
blame everything on a slower demand for Muse, which are not
substantiated by the facts as we know them. The only positive
point they make is that refills have steadily risen to a
recent range of 4000-5000 a week "enough to make MUSE quite
a successful drug launch, piling up sales of $100 million
for the nine months earning Vivus $31 million, or 86 cents
a share". Then they go on to attack profit margins, which
again is not substantiated. With so many promising aspects
of Muse, why are these business publications favoring Viagra?
At this point we don't know much about it's performance and
how it will fare in the marketplace other than what Pfizer
tells us or people speculate. Don't let us be naive about the
power of PR and what goes on in the media.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News